HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SKB BIO-B

285.400

-3.600-1.25%

Volume:811.90K

Turnover:232.78M

Market Cap:64.79B

PE:-223.03

High:294.000

Open:285.000

Low:275.000

Close:289.000

Loading ...

Overview Company News Filings

SKB Biopharma's NDA for Breast Cancer Drug Accepted by Chinese Regulator

MT Newswires Live

Sichuan Kelun-Biotech Biopharmaceutical - New Drug Application for Core Product Trastuzumab Botidotin Accepted by China Nmpa

THOMSON REUTERS

China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk

SKB Biopharmaceutical Gets China Marketing Nod for Nasopharyngeal Cancer

MT Newswires Live

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Anti-Pd-L1 Tagitanlimab Approved For Marketing By Nmpa Of China

Sichuan Kelun-Biotech Biopharmaceutical - Anti-Pd-L1 Tagitanlimab Approved for Marketing by Nmpa of China

THOMSON REUTERS

SKB Biopharma Avails of 300 Million Yuan Structured Deposits from China's Industrial Bank

MT Newswires Live

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe 2 Structured Deposits From Industrial Bank

Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe 2 Structured Deposits From Industrial Bank of RMB170 Mln and RMB130 Mln

THOMSON REUTERS

Chinese Regulator Approves Sichuan Kelun-Biotech's Investigational New Drug Application for Tumor Drug

MT Newswires Live

Sichuan Kelun-Biotech Biopharmaceutical - Investigational New Drug Approval for Skb500 by Nmpa

THOMSON REUTERS

Stock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug

Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod Marketing Approval for Breast Cancer Drug; Share Up 5%

MT Newswires Live

Sichuan Kelun-Biotech Biopharmaceutical - Got Marketing Authorization in China for Trop2-Directed Antibody-Drug Conjugate

THOMSON REUTERS

Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing by Nmpa of China

THOMSON REUTERS

Sichuan Kelun-Biotech Biopharmaceutical Gets Investigational New Drug Approval for Tumor Drug from Chinese Regulator

MT Newswires Live

BRIEF-Sichuan Kelun-Biotech Biopharma Announces Investigational New Drug Approval For SKB501 By NMPA China

Sichuan Kelun-Biotech Biopharmaceutical - Investigational New Drug Approval for Skb501 by Nmpa China

THOMSON REUTERS

China Approves Clinical Trial for SKB's Anti-Tumor Drug; Shares Fall 4%

MT Newswires Live

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Investigational New Drug Approval For SKB571 By NMPA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06990/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":285.4,"timestamp":1744877289037,"preClose":289,"halted":0,"volume":811904,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-1.2796556756154556,"marketStatus":"Market Closed","change":-3.6,"latestTime":"04-17 16:08:09","open":285,"high":294,"low":275,"amount":232778521,"amplitude":0.065744,"askPrice":286.4,"askSize":300,"bidPrice":285.4,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.2796556756154556,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":289,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":1.0355934219983844,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":131000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.279656,"volumeRatio":1.0355934219983844,"shares":227000000,"dividePrice":0,"high":294,"amplitude":0.065744,"preClose":289,"low":275,"week52Low":120.2,"pbRate":"18.42","psRate":"31.52","week52High":346,"institutionHeld":0,"latestPrice":285.4,"eps":-1.2796556756154556,"divideRate":0,"volume":811904,"delay":0,"ttmEps":-1.2796556756154556,"open":285,"prevYearClose":163.3,"prevWeekClose":302,"prevMonthClose":290.8,"prevQuarterClose":290.8,"fiveDayClose":280.8,"twentyDayClose":259.4,"sixtyDayClose":162.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2501270463","title":"SKB Biopharma's NDA for Breast Cancer Drug Accepted by Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2501270463","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501270463?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:07","pubTimestamp":1736251629,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical's  new drug application  for trastuzumab botidotin was accepted by China's National Medical Products Administration, a Tuesday bourse filing said.The product is indicated for the treatment of adult patients with HER2 positive unresectable or metastatic breast cancer who have received at least one prior anti-HER2 therapy, according to the biopharmaceutical company.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2501279029","title":"Sichuan Kelun-Biotech Biopharmaceutical - New Drug Application for Core Product Trastuzumab Botidotin Accepted by China Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2501279029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501279029?lang=en_us&edition=fundamental","pubTime":"2025-01-07 18:55","pubTimestamp":1736247312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O30N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2501292221","title":"China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2501292221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501292221?lang=en_us&edition=fundamental","pubTime":"2025-01-07 16:23","pubTimestamp":1736238180,"startTime":"0","endTime":"0","summary":"0822 GMT - China's healthcare sector will likely get a significant boost from national policies in 1Q, Citi analysts write in a note. This year marks the start of the most positive structural change in the industry, as it will be the first time that China's public healthcare system is able to include commercial insurance providers as significant payers, they say. The brokerage recommends buying shares in companies that will be direct beneficiaries of the reform. These include pharmaceutical and biopharmaceutical firms, pharmaceutical distributors and medical device companies. Citi's top picks include Jiangsu Hengrui Medicine, Hansoh Pharmaceutical, SSY Group, Akeso, Sichuan Kelun-Biotech Biopharmaceutical, Mindray Medical, Sinopharm Group, WuXi AppTec, Wuxi Biologics and Gushengtang. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","LU0140636845.USD","LU1064131003.USD","LU0359202008.SGD","BK4137","LU0516422952.EUR","LU0856984785.SGD","LU0979878070.USD","LU1242518857.USD","LU1328615791.USD","03692","LU0516422440.USD","IE00B543WZ88.USD","LU0359201612.USD","LU0516423174.USD","LU1880383366.USD","SHTDY","LU0640798160.USD","BK1583","BK0188","BK1191","BK1589","LU0326950275.SGD","603259","LU0348784397.USD","BK1574","LU0588546209.SGD","LU0819121731.USD","BK1219","LU1997245094.SGD","09926","BK0012","BK1610","LU0456846285.SGD","LU0348735423.USD","LU0405327148.USD","600276","02269","02273","LU0039217434.USD","LU0348825331.USD","HCSG","LU0052750758.USD","06990","LU0196878994.USD","01099","LU0516422366.SGD","02005","LU2460026573.USD","BK0196"],"gpt_icon":0},{"id":"2500914427","title":"SKB Biopharmaceutical Gets China Marketing Nod for Nasopharyngeal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2500914427","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500914427?lang=en_us&edition=fundamental","pubTime":"2025-01-02 16:38","pubTimestamp":1735807112,"startTime":"0","endTime":"0","summary":"China's medical products administrator granted Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) marketing approval for a drug for recurrent or metastatic nasopharyngeal cancer, according to a Tuesda","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2495667952","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Anti-Pd-L1 Tagitanlimab Approved For Marketing By Nmpa Of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2495667952","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495667952?lang=en_us&edition=fundamental","pubTime":"2024-12-31 18:33","pubTimestamp":1735641194,"startTime":"0","endTime":"0","summary":"Dec 31 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * ANTI-PD-L1 TAGITANLIMAB APPROVED FOR MARKETING BY NMPA OF CHINAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Anti-Pd-L1 Tagitanlimab Approved For Marketing By Nmpa Of China","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2495166491","title":"Sichuan Kelun-Biotech Biopharmaceutical -  Anti-Pd-L1 Tagitanlimab Approved for Marketing by Nmpa of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2495166491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495166491?lang=en_us&edition=fundamental","pubTime":"2024-12-31 17:56","pubTimestamp":1735638999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241231:nFWN3NV0L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2492922846","title":"SKB Biopharma Avails of 300 Million Yuan Structured Deposits from China's Industrial Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2492922846","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492922846?lang=en_us&edition=fundamental","pubTime":"2024-12-18 14:04","pubTimestamp":1734501852,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  availed of two structured deposits from Industrial Bank  worth a total of 300 million yuan on Tuesday, according to a same-day filing with the Hong Kong exchange.The 170 million yuan deposit has a 97-day term set to mature March 25, 2025. It has an expected annualized floating rate of return of 1.3% or 2.5% per annum, the filing said.The 130 million yuan deposit has a 189-day term maturing June 25, 2025 and an expected annualized floating rate of return of 1.5% or 2.5% per annum, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","LU0572939691.SGD","BK0278","BK0012","LU1580142542.USD","LU1328615791.USD","LU1781817850.SGD","BK1161","LU1048596156.SGD","LU0821914370.USD","BK0028","BK0015","LU0572940350.SGD","LU0264606111.USD","BK0183","601166","BK0187","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2492296932","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe 2 Structured Deposits From Industrial Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2492296932","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492296932?lang=en_us&edition=fundamental","pubTime":"2024-12-17 23:15","pubTimestamp":1734448522,"startTime":"0","endTime":"0","summary":"Dec 17 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * TO SUBSCRIBE 2 STRUCTURED DEPOSITS FROM INDUSTRIAL BANK OF RMB170 MILLION AND RMB130 MILLION Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2492966692","title":"Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe 2 Structured Deposits From Industrial Bank of RMB170 Mln and RMB130 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2492966692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492966692?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:57","pubTimestamp":1734447447,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nFWN3NI0IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2488316881","title":"Chinese Regulator Approves Sichuan Kelun-Biotech's Investigational New Drug Application for Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488316881","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488316881?lang=en_us&edition=fundamental","pubTime":"2024-12-04 18:01","pubTimestamp":1733306475,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  received a clinical trial notice approving the investigational new drug application for SKB500 from China's National Medical Products Administration, a Wednesday bourse filing said.SKB500 is intended for the treatment of advanced solid tumors, according to the biopharmaceutical company.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2488159787","title":"Sichuan Kelun-Biotech Biopharmaceutical - Investigational New Drug Approval for Skb500 by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2488159787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488159787?lang=en_us&edition=fundamental","pubTime":"2024-12-04 16:43","pubTimestamp":1733301832,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N412T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"1136371661","title":"Stock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1136371661","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136371661?lang=en_us&edition=fundamental","pubTime":"2024-11-27 14:32","pubTimestamp":1732689154,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  saw its shares surge 7.36% in the intraday session on Wednesday, outperforming the broader market. The rally was fueled by the company receiving marketing authorization from China's National Medical Products Administration  for its breast cancer drug.The approved drug, sacituzumab tirumotecan , is designed to treat advanced or metastatic triple-negative breast cancer  in adult patients who have already undergone at least two prior systemic therapies, incl","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06990"],"gpt_icon":0},{"id":"2486147897","title":"Sichuan Kelun-Biotech Biopharmaceutical Gets NMPA's Nod Marketing Approval for Breast Cancer Drug; Share Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486147897","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486147897?lang=en_us&edition=fundamental","pubTime":"2024-11-27 14:28","pubTimestamp":1732688887,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  said China's National Medical Products Administration  gave a marketing authorization for its breast cancer drug, according to a Wednesday filing with the Hong Kong bourse.The drug is designed for adults with advanced or metastatic triple-negative breast cancer  that cannot be surgically removed. It targets TROP2 using the antibody-drug conjugate sacituzumab tirumotecan , intended for patients who have already undergone at least two systemic treatments, including one for advanced or metastatic.The pharmaceutical company's stocks have increased by 5% in recent trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2486847893","title":"Sichuan Kelun-Biotech Biopharmaceutical - Got Marketing Authorization in China for Trop2-Directed Antibody-Drug Conjugate","url":"https://stock-news.laohu8.com/highlight/detail?id=2486847893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486847893?lang=en_us&edition=fundamental","pubTime":"2024-11-27 12:07","pubTimestamp":1732680430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MX0RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2486893841","title":"Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing by Nmpa of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2486893841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486893841?lang=en_us&edition=fundamental","pubTime":"2024-11-27 12:06","pubTimestamp":1732680380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MX14K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2486740520","title":"Sichuan Kelun-Biotech Biopharmaceutical Gets Investigational New Drug Approval for Tumor Drug from Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2486740520","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486740520?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:39","pubTimestamp":1732624795,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  obtained approval for the investigational new drug application for its SKB501 from China's National Medical Products Administration on Monday, a same-day bourse filing said.SKB501 is intended to be used for the treatment of advanced solid tumors, a biopharmaceutical company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2486470621","title":"BRIEF-Sichuan Kelun-Biotech Biopharma Announces Investigational New Drug Approval For SKB501 By NMPA China","url":"https://stock-news.laohu8.com/highlight/detail?id=2486470621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486470621?lang=en_us&edition=fundamental","pubTime":"2024-11-25 18:11","pubTimestamp":1732529498,"startTime":"0","endTime":"0","summary":"Nov 25 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB501 BY NMPA CHINA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2486770432","title":"Sichuan Kelun-Biotech Biopharmaceutical - Investigational New Drug Approval for Skb501 by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2486770432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486770432?lang=en_us&edition=fundamental","pubTime":"2024-11-25 17:07","pubTimestamp":1732525666,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nFWN3MV0A0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2484618567","title":"China Approves Clinical Trial for SKB's Anti-Tumor Drug; Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484618567","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484618567?lang=en_us&edition=fundamental","pubTime":"2024-11-18 14:13","pubTimestamp":1731910433,"startTime":"0","endTime":"0","summary":"China's medical products administrator approved Sichuan Kelun-Biotech Biopharmaceutical's  clinical trial for its SKB535 drug for advanced solid tumors, according to a Monday filing with the Hong Kong Exchange.SKB535 is the NMPA's first approved pilot project under the agency's optimized clinical trial review scheme.SKB signed a license and collaboration agreement with MSD for the development of SKB535 and will be entitled to milestone payments and other royalties from net sales, the filing said.Shares fell 4% during Monday's trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2484616276","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Investigational New Drug Approval For SKB571 By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2484616276","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484616276?lang=en_us&edition=fundamental","pubTime":"2024-11-18 09:34","pubTimestamp":1731893689,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Investigational New Drug Approval For SKB571 By NMPANov 18 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:INVESTIGATIONAL NEW DRU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MN0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":66,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post Market","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"Post Market","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744646400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-04-17","current":-228.611836,"percent":0.03653,"low":-257.850518,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"high":-21.029201,"avg":-97.473315,"sd":62.021902,"marketCap":64862287200},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200}],"updateTime":1745143783441}}}